RCKT insider filings

ROCKET PHARMACEUTICALS, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-20. Screen RCKT transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 7 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Wilson Martin — General Counsel4—4 legs · 133,517 sh · $394,947—
Shah Gaurav — CEO2—2 legs · 5,236 sh · $11,621—
Chaudhuri Sarbani — See Remarks1—1 leg · 4,872 sh · $11,337—

Recent insider filings — ROCKET PHARMACEUTICALS, INC.

FiledFormInsiderReported transactionsSource
2026-11-204Shah Gaurav — CEOSale (S): 2,216 @ $2.18EDGAR
2026-11-204Wilson Martin — General CounselSale (S): 677 @ $2.18EDGAR
2026-11-174Shah Gaurav — CEOSale (S): 3,020 @ $2.25EDGAR
2026-11-174Wilson Martin — General CounselSale (S): 4,087 @ $2.25EDGAR
2026-11-124Chaudhuri Sarbani — See RemarksSale (S): 4,872 @ $2.33EDGAR
2026-11-094Wilson Martin — General CounselSale (S): 53,389 @ $2.39EDGAR
2026-09-154Wilson Martin — General CounselSale (S): 75,364 @ $3.40EDGAR
2026-08-204Wilson Martin — General CounselSale (S): 631 @ $3.38EDGAR
2026-08-204Shah Gaurav — CEOSale (S): 2,293 @ $3.38EDGAR
2026-08-174Wilson Martin — General CounselSale (S): 3,493 @ $3.38EDGAR
2026-08-174Shah Gaurav — CEOSale (S): 2,837 @ $3.38EDGAR
2026-08-134Chaudhuri Sarbani — See RemarksSale (S): 4,701 @ $3.50EDGAR
2026-08-134Stevens Christopher James — Chief Operating OfficerSale (S): 36,658 @ $3.50EDGAR
2026-08-054Stevens Christopher James — Chief Operating OfficerGrant/award (A): 73,313 @ $0 · Grant/award (A): 101,428 (derivative) @ $0EDGAR
2026-08-054SOUTHWELL DAVID P — DirectorOther (J): 150,000 @ $0EDGAR
2026-07-064WONG RODERICK — Director, 10% ownerGrant/award (A): 27,832 @ $0 · Grant/award (A): 78,960 (derivative) @ $0EDGAR
2026-07-064Fong Peter — DirectorGrant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0EDGAR
2026-07-064Dolsten Mikael — DirectorGrant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0EDGAR
2026-07-064Malik Fady Ibraham — DirectorGrant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0EDGAR
2026-07-064BOESS CARSTEN — DirectorGrant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0EDGAR
2026-07-064SOUTHWELL DAVID P — DirectorGrant/award (A): 22,862 @ $0 · Grant/award (A): 64,860 (derivative) @ $0EDGAR
2026-05-284Militello John — See RemarksDisposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 2,000 (derivative) · +11 moreEDGAR
2026-05-264Shah Gaurav — CEOOption exercise (M): 76,490 @ $1.69 · Sale (S): 55,684 @ $3.09 · Option exercise (M): 76,490 (derivative) @ $1.69EDGAR
2026-05-214Shah Gaurav — CEOSale (S): 2,409 @ $3.01EDGAR
2026-05-214Wilson Martin — General CounselSale (S): 662 @ $3.01EDGAR
2026-05-214Militello John — See RemarksSale (S): 384 @ $3.01EDGAR
2026-05-144Wilson Martin — General CounselSale (S): 3,361 @ $3.61EDGAR
2026-05-144Shah Gaurav — CEOSale (S): 2,728 @ $3.61EDGAR
2026-05-144Militello John — See RemarksSale (S): 855 @ $3.61EDGAR
2026-05-114Chaudhuri Sarbani — See RemarksSale (S): 17,650 @ $3.84EDGAR
2026-02-204Militello John — See RemarksSale (S): 1,157 @ $3.34EDGAR
2026-02-204Shah Gaurav — CEOSale (S): 5,990 @ $3.34EDGAR
2026-02-204Wilson Martin — General CounselSale (S): 1,376 @ $3.34EDGAR
2026-02-184Wilson Martin — General CounselSale (S): 12,253 @ $3.31EDGAR
2026-02-184Militello John — See RemarksSale (S): 3,726 @ $3.31EDGAR
2026-02-184Shah Gaurav — CEOSale (S): 12,279 @ $3.31EDGAR
2026-02-134Shah Gaurav — CEOGrant/award (A): 286,028 @ $0 · Grant/award (A): 870,648 (derivative) @ $0EDGAR
2026-02-134Militello John — See RemarksGrant/award (A): 29,982 @ $0 · Grant/award (A): 45,018 (derivative) @ $0EDGAR
2026-02-134Wilson Martin — General CounselGrant/award (A): 311,813 @ $0 · Grant/award (A): 468,187 (derivative) @ $0EDGAR
2026-02-134Rizvi Syed Ali-aamir — Chief Medical OfficerGrant/award (A): 61,963 @ $0 · Grant/award (A): 93,037 (derivative) @ $0EDGAR
2026-02-134Stevens Christopher James — Chief Operating OfficerGrant/award (A): 61,963 @ $0 · Grant/award (A): 93,037 (derivative) @ $0EDGAR
2026-02-134Chaudhuri Sarbani — See RemarksGrant/award (A): 125,924 @ $0 · Grant/award (A): 189,076 (derivative) @ $0EDGAR
2026-01-064Bjork Elisabeth — DirectorPurchase (P): 10,000 @ $3.44EDGAR
2025-11-204Militello John — See RemarksSale (S): 1,086 @ $2.98EDGAR
2025-11-204Schwartz Jonathan David — See RemarksSale (S): 2,545 @ $2.98EDGAR
2025-11-204Shah Gaurav — CEO, DirectorSale (S): 6,276 @ $2.98EDGAR
2025-11-204Wilson Martin — General CounselSale (S): 1,646 @ $2.98EDGAR
2025-11-104Wilson Martin — General CounselGrant/award (A): 100,000 @ $0EDGAR
2025-10-164Militello John — See RemarksSale (S): 19,841 @ $3.96 · Sale (S): 5,514 @ $3.96 · Sale (S): 3,005 @ $3.97 · Sale (S): 558 @ $3.98EDGAR
2025-10-084Rizvi Syed Ali-aamir — Chief Medical OfficerGrant/award (A): 283,018 @ $0 · Grant/award (A): 62,893 @ $0 · Grant/award (A): 383,854 (derivative) @ $0EDGAR

Recent 8-K events — ROCKET PHARMACEUTICALS, INC.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-068-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-158-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-278-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-08-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-038-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-308-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-06-128-K2.01 — Completion of Acquisition or Disposition of Assets
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-218-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=RCKT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs